id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-328352-l1q4uvxl	Borlongan, Mia C.	The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy	2020-08-25		.txt	text/plain	3236	158	45	This investigational treatment uses plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2, the virus that causes COVID-19. Subsequent to the Spanish flu pandemic, the treatment with convalescent plasma has been studied in similar outbreaks of respiratory infections, such as the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic 19, 20 . (2) Another small study on ten severe COVID-19 Chinese patients revealed that nine patients displayed increased neutralizing antibody titers, and the viral load in seven patients becoming undetectable by day seven post-infusion of convalescent plasma, but only 3 exhibited improved respiratory function 23 . In all these five clinical studies, it is understandable that because convalescent plasma treatment remains experimental, the target population is initially the severe or critically ill patients, who have high mortality and worst morbidity, which may mask the potential functional benefits of the treatment.	./cache/cord-328352-l1q4uvxl.txt	./txt/cord-328352-l1q4uvxl.txt